Skip to main content
ZIM Laboratories Limited logo

ZIM Laboratories Limited — Investor Relations & Filings

Ticker · ZIMLAB ISIN · INE518E01015 LEI · 335800YPYG1O3ML66R52 BSE.NS Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2026-05-19 Board/Management Inform…
Country IN India
Listing BSE.NS ZIMLAB

About ZIM Laboratories Limited

https://www.zimlab.in/

ZIM Laboratories Limited is a research-driven organization specializing in the development and manufacturing of innovative drug delivery solutions. The company focuses on enhancing the efficacy and patient compliance of generic medicines through advanced formulation technologies. Its core product portfolio includes Oral Disintegrating Films (ODF), Oral Disintegrating Tablets (ODT), pellets, and taste-masked granules. Utilizing proprietary technology platforms like Thinoral, the company provides differentiated products across various therapeutic segments, including central nervous system, cardiovascular, and gastrointestinal health. ZIM Laboratories offers end-to-end services from product development and clinical trials to commercial manufacturing. The organization serves a global clientele, providing value-added generic formulations that address specific patient needs such as ease of administration and rapid onset of action.

Recent filings

Filing Released Lang Actions
Appointment of M/s. Dhananjay V. Joshi & Associates, Cost Accountants as the Cost Auditor for the F.Y. 2026-27
Board/Management Information Classification · 95% confidence The document is an official intimation to stock exchanges about the appointment of a Cost Auditor for the fiscal year 2026-27. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and includes details about the appointment as per regulatory requirements. The document is a notification of a board decision rather than a financial report or audit report itself. It does not contain financial statements or audit results but is an announcement of a management decision related to audit appointment. Therefore, it fits best under Board/Management Information (MANG) as it relates to a change in company management or appointments.
2026-05-19 English
Outcome of the Board meeting held on 19.05.2026
Audit Report / Information Classification · 98% confidence The document consists primarily of the Independent Auditor’s Report on the annual consolidated financial results (and review of quarterly results) for the year/quarter ended 31 March 2026, including the auditor’s opinion, basis for opinion, and auditor responsibilities. It is not the full annual report, nor simply an announcement of publication, but a standalone audit report as defined under our taxonomy. Therefore, it is classified as an Audit Report/Information. FY 2026
2026-05-19 English
Change in Auditors
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the appointment of a Cost Auditor for the fiscal year 2026-27. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and includes details about the appointment as per regulatory requirements. The document is an announcement of a board decision rather than a financial report or audit report itself. It does not contain financial statements, audit results, or detailed management discussion. The content fits the category of Board/Management Information (MANG) as it announces a change in a key company appointment related to governance and compliance.
2026-05-19 English
Outcome of Board Meeting
Audit Report / Information Classification · 87% confidence The document is a notice to stock exchanges under SEBI LODR Reg 30 announcing the outcome of the board meeting, specifically the approval of the audited standalone and consolidated financial statements and quarterly and annual financial results for year ended March 31, 2026, and encloses the independent auditor’s report. It does not constitute a management discussion or full annual report, but is primarily the standalone audit report on the financial results. This matches the “Audit Report / Information” category. FY 2026
2026-05-19 English
Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that Q4&FY26 Earnings ....
Regulatory Filings Classification · 87% confidence The document is an announcement under SEBI Listing Regulations to inform stock exchanges about the scheduling of the Q4 & FY26 earnings conference call. It contains no financial results or presentation materials, nor is it a transcript. It is a regulatory disclosure/fallback announcement, fitting the RNS category.
2026-05-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 80% confidence The document is a regulatory notice under SEBI Listing Regulations informing exchanges and investors of the scheduling details for the Q4 & FY26 earnings conference call. It does not contain financial results (so it is not an Earnings Release or Interim Report), nor is it a transcript, presentation, or other specific filing. It is a general disclosure under Regulation 30, falling into the fallback category for miscellaneous regulatory announcements (RNS).
2026-05-13 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.